Advanced Research and Invention Agency Bill (Third sitting)
Debate between Dawn Butler and Aaron Bell(3 years ago)
Public Bill CommitteesRead Full debate Read Hansard Text Read Debate Ministerial Extracts
Dawn Butler
It is a pleasure to serve under your chairmanship, Ms McVey. I do not think anyone will vote against the amendment, because all it seeks to do is ensure that there is a memorandum of understanding between ARIA and UK Research and Innovation about how they will work together. The two organisations will be working on the same themes, though doing things slightly differently, and they need to communicate. I am happy to give way to anyone who thinks it is not a good idea that UKRI and ARIA communicate. The amendment is practical and sensible and seeks only to clarify how they would work together.
Our evidence session was informative. Dame Ottoline Leyser from UKRI said:
“The people employed at ARIA will absolutely need to understand deeply what UKRI is doing and what the opportunities are across that research base in order to deliver their vision. I would expect a very close working relationship with ARIA to allow that to happen.”––[Official Report, Advanced Research and Invention Agency Public Bill Committee, 14 April 2021; c. 6, Q3.]
When she said that, I thought that the relationship must have been written in the legislation and I had missed something, because she said it as though it was going to happen. I went back to the Bill to have a look, but nothing in it says that UKRI and ARIA have to work together or at least know what each other is doing. I thought that quite strange. When I asked her how she expected that to happen, she said “naturally”. We in Parliament make laws and legislation; we do not leave things to happen naturally if we can we put them on the statute book. The amendment seeks only to have a memorandum of understanding between the already established UKRI and the newly established ARIA.
If the Committee votes against the amendment, people outside will not understand. They will ask, “Why don’t you want a memorandum of understanding?” Everything cannot be done just on trust. We have trust and transparency, but right now ARIA has neither, and it will not be subject to freedom of information rules. It is the wrong approach to say to people outside, “We are going to give £800 million to an organisation that will have no oversight, no FOI and no link to UKRI.” How would that be sensible, especially when—I say this gently—the Government are caught up in sleaze at the moment? That would not help at all. People will say, “You want £800 million to go to whom and to do what?”
Ultimately, we know that men of a certain age get these opportunities, and these men tend to fail upwards. Without the amendment, we are saying that we will allow people to fail upwards and we will not know what they are doing because failure will be part of what ARIA is. We accept that failure can be a part of ARIA, but there needs to be some oversight and connection to the already established UKRI.
Aaron Bell (Newcastle-under-Lyme) (Con)
I thank the hon. Member for her service on the Science and Technology Committee with me, where we have been discussing this issue and the covid crisis over the last year. She made a point about men of a certain age. Last year, it was two women of a certain age—Dido Harding and Kate Bingham—who helped to respond to coronavirus. At the time, the Opposition made various allegations of cronyism, particularly about Kate Bingham, which ought to be withdrawn now that we have seen the success of what can happen when we take away some of the administrative burdens, focus clear-mindedly on a key goal and get it delivered. Making these allegations of sexism when we have had two women leading our response to coronavirus is not appropriate.
Dawn Butler
I thank the hon. Member for his service on the Science and Technology Committee, where we often agree and very often disagree. Of course we praise what goes well, but let us not forget that £14 million was spent on a test and trace system that was scrapped, or that Northern Ireland spent £1 million on a test and trace system that works perfectly well. Let us not forget those facts. Now, we are talking about £800 million.
Professor Pierre Azoulay said,
“It is important not to put those two agencies in competition; they both have a role to play.”—[Official Report, Advanced Research and Invention Agency Bill (Second sitting), 14 April 2021; c. 46]
Both agencies have a role to play; let them work together. Let us work on the premise that it will be a success.
Aaron Bell
One of the reasons why things look that way from the outside is the accusations made by the Opposition. I have an example. The hon. Lady was not here earlier—I completely accept that she had a reason for that—when I referred to Kate Bingham’s appointment, and the £670,000 spent last year on a crucial campaign to get hard-to-reach groups not only to take part in vaccine trials but to take the vaccine. At the time, the Leader of the Opposition said:
“You cannot justify that sort of money being spent”,
and the deputy leader of the Labour party said, “This cronyism stinks.” After what we saw last year, I think it a little rich of the Opposition to go round suggesting that this is the problem, when, as my hon. Friend the Member for South Basildon and East Thurrock said, the Science and Technology Committee, and all the science community, are very engaged. The idea that there would be scientific sleaze is frankly risible.
Advanced Research and Invention Agency Bill (First sitting)
Debate between Dawn Butler and Aaron Bell(3 years ago)
Public Bill CommitteesRead Full debate Read Hansard Text Read Debate Ministerial Extracts
Dawn Butler
Q
Professor Leyser: At the moment, most of our funding opportunities require people to apply for a research grant. People coding at home have a hard time applying for research grants, because it is a system with financial checks and so on. Applying for a research grant is a non-trivial activity, whereas winning a research prize, where there is no application process and you just get on with it, is doable. We are very interested in that wider range of funding mechanisms and in how we can learn from the work of Nesta, and, in the future, the work of ARIA to reach a wider range of people. But at the moment, we work on a largely open-call process; it is really effective because it is completely open, but it none the less creates barriers for people who do not have the infrastructure and administrative support to help them submit those kinds of grant applications.
Aaron Bell (Newcastle-under-Lyme) (Con)
Q
Following on from Dame Ottoline’s answer to Ms Butler, obviously, the purpose is to expand ARIA to cover areas that are not already well covered, but it also seems to be to try to pick up the pace of research and innovation. We have seen that that is possible through crises such as coronavirus. Can you explain how the pace can be picked up by some of the things that you do at Nesta and whether that would carry across to what ARIA is going to do?
Tris Dyson: I think it helps to pick things, to say, “We want to achieve x within the next two or three years” and to give people a degree of certainty about what outcomes you are going to fund and why. It happens naturally, anyway. Coronavirus is a crisis that has created a rush for R&D. It has also shown, on the drug development or vaccine side, what a combination of funding and relatively agile thinking, including from regulators in conjunction, can do in order to improve outcomes and achieve things. A challenge prize creates that in a positive sense; it essentially says, “We are going to solve for x and award funding on that basis.” That helps speed things up.
Related to the previous question, with a grant model approach, you are funding inputs and costs primarily. People put in a proposal for half a million pounds and say, “We are going to do x and this is what the associated costs are going to be.” Inherently, your risk threshold is going to be different, because you are anticipating whether this an investment that means they are going to be able to spend that money well and achieve x. You are going to look at track records, their financial history and their institutional strengths. You are going to make a judgment on whether to fund A versus B. That lends itself more towards funding the usual suspects than an outcome-based model, where you say, “It is not important to us who solves for x as long as somebody does.” In reality, you tend to blend these models. It is not like there is a pure challenge prize model that does not involve other types of funding mechanisms as well.